JP2005519035A5 - - Google Patents

Download PDF

Info

Publication number
JP2005519035A5
JP2005519035A5 JP2003548857A JP2003548857A JP2005519035A5 JP 2005519035 A5 JP2005519035 A5 JP 2005519035A5 JP 2003548857 A JP2003548857 A JP 2003548857A JP 2003548857 A JP2003548857 A JP 2003548857A JP 2005519035 A5 JP2005519035 A5 JP 2005519035A5
Authority
JP
Japan
Prior art keywords
cells
mouse
spots
peptide
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2003548857A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005519035A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2002/013791 external-priority patent/WO2003047602A1/en
Publication of JP2005519035A publication Critical patent/JP2005519035A/ja
Publication of JP2005519035A5 publication Critical patent/JP2005519035A5/ja
Withdrawn legal-status Critical Current

Links

JP2003548857A 2001-12-07 2002-12-05 免疫促進性オリゴデオキシヌクレオチド Withdrawn JP2005519035A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AT19242001 2001-12-07
PCT/EP2002/013791 WO2003047602A1 (en) 2001-12-07 2002-12-05 Immunostimulatory oligodeoxynucleotides

Publications (2)

Publication Number Publication Date
JP2005519035A JP2005519035A (ja) 2005-06-30
JP2005519035A5 true JP2005519035A5 (cg-RX-API-DMAC10.html) 2006-01-26

Family

ID=3689335

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003548857A Withdrawn JP2005519035A (ja) 2001-12-07 2002-12-05 免疫促進性オリゴデオキシヌクレオチド

Country Status (6)

Country Link
US (1) US20050250716A1 (cg-RX-API-DMAC10.html)
EP (1) EP1450821A1 (cg-RX-API-DMAC10.html)
JP (1) JP2005519035A (cg-RX-API-DMAC10.html)
AU (1) AU2002358616A1 (cg-RX-API-DMAC10.html)
CA (1) CA2452909A1 (cg-RX-API-DMAC10.html)
WO (1) WO2003047602A1 (cg-RX-API-DMAC10.html)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001022972A2 (en) * 1999-09-25 2001-04-05 University Of Iowa Research Foundation Immunostimulatory nucleic acids
EP1390494A2 (en) 2001-05-21 2004-02-25 Intercell AG Method for stabilising of nucleic acids
JP2005533855A (ja) 2002-07-24 2005-11-10 インターツェル・アクチェンゲゼルシャフト 病原性ウイルスからの別のリーディングフレームによりコードされる抗原
EP1537418A2 (en) 2002-09-13 2005-06-08 Intercell AG Method for isolating hepatitis c virus peptides
AU2004224746B2 (en) 2003-03-24 2009-04-23 Valneva Austria Gmbh Improved vaccines
US7635487B2 (en) 2003-04-15 2009-12-22 Intercell Ag S. pneumoniae antigens
CA2530062A1 (en) * 2003-07-11 2005-01-20 Intercell Ag Hcv vaccines
AU2004263037B2 (en) * 2003-08-11 2011-02-10 Japan As Represented By The Director-General Of National Institute Of Infectious Diseases Novel vaccine containing adjuvant capable of inducing mucosal immunity
JP4817599B2 (ja) * 2003-12-25 2011-11-16 独立行政法人科学技術振興機構 免疫活性増強剤とこれを用いた免疫活性の増強方法
JP2008507537A (ja) * 2004-07-23 2008-03-13 アドバイシーズ,インコーポレイテッド 予防接種レスポンスを増強する成長ホルモン放出ホルモン
WO2007062107A2 (en) 2005-11-25 2007-05-31 Coley Pharmaceutical Gmbh Immunostimulatory oligoribonucleotides
EP2292647A3 (en) 2006-07-07 2011-06-08 Intercell AG Small Streptococcus pyogenes antigens and their use
EP2289906A1 (en) 2006-09-15 2011-03-02 Intercell AG Borrelia antigens
EP1923069A1 (en) 2006-11-20 2008-05-21 Intercell AG Peptides protective against S. pneumoniae and compositions, methods and uses relating thereto
EP2266592A3 (en) 2007-01-12 2012-08-08 Intercell AG Protective proteins of S. agalactiae, combinations thereof and methods of using the same
CA2685805A1 (en) 2007-05-02 2008-11-13 Intercell Ag Klebsiella antigens
EP2511291A3 (en) 2007-06-18 2012-11-07 Intercell AG Chlamydia antigens
AU2009226949A1 (en) 2008-03-17 2009-09-24 Intercell Ag Peptides protective against S. pneumoniae and compositions, methods and uses relating thereto
ES2569907T3 (es) 2008-06-27 2016-05-13 Zoetis Services Llc Composiciones adyuvantes novedosas
EP2424882A2 (en) 2009-02-05 2012-03-07 Intercell AG Peptides protective against e. faecalis, methods and uses relating thereto
EP2405938A2 (en) 2009-02-13 2012-01-18 Intercell AG Nontypable haemophilus influenzae antigens
US8454547B2 (en) 2009-02-25 2013-06-04 The Invention Science Fund I, Llc Device, system, and method for controllably reducing inflammatory mediators in a subject
WO2011031139A1 (en) 2009-09-09 2011-03-17 Universiteit Utrecht Holding B.V. An ataq protein or a part thereof as a vaccine
SA110310855B1 (ar) 2009-11-13 2014-09-16 Laboratories Leti S L Unipersonal استخدام مصدر l3 و/ أو l5 كلقاح أو كوسيلة تشخيصية لمرض طفيلي
KR101907434B1 (ko) 2010-09-03 2018-10-12 발네바 오스트리아 게엠베하 C. 디피실의 a 독소 및 b 독소 단백질의 분리된 폴리펩타이드 및 이의 용도
US9187751B2 (en) 2010-11-10 2015-11-17 Laboratorios Leti, S.L. Adjuvant
DE102011018499A1 (de) 2011-04-23 2012-10-25 Emc Microcollections Gmbh Topische Nanopartikel-Vakzine zur Immunstimulation der dendritischen Zellen in der Haut
PT2941233T (pt) * 2013-01-07 2020-11-13 Univ Pennsylvania Composições e métodos para tratar linfoma cutâneo de células t
KR20200039025A (ko) 2013-09-19 2020-04-14 조에티스 서비시즈 엘엘씨 유성 아쥬반트
MX391930B (es) 2015-01-16 2025-03-21 Zoetis Services Llc Vacuna contra la fiebre aftosa.
WO2017046409A1 (en) 2015-09-18 2017-03-23 Rijksuniversiteit Groningen Long chain inulin for stimulating an immune response
KR20220010478A (ko) 2019-05-20 2022-01-25 발네바 에스이 기도 감염의 치료 또는 예방용 서브유닛 백신

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3725545A (en) * 1971-02-03 1973-04-03 R Maes Enhancement of antibody production by nucleic acid-polycation complexes
US3906092A (en) * 1971-11-26 1975-09-16 Merck & Co Inc Stimulation of antibody response
DK0610396T3 (da) * 1991-10-23 2001-01-29 Baylor College Medicine Fingeraftryksidentifikation af bakteriestammer med anvendelse af repetitiv DNA-sekvensamplifikation
AU713040B2 (en) * 1994-07-15 1999-11-18 University Of Iowa Research Foundation, The Immunomodulatory oligonucleotides
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
FI970588A7 (fi) * 1994-08-12 1997-04-11 Wellstat Therapeutics Corp Menetelmät verenmyrkytyksen tai tulehdussairauksien hoitamiseksi oksipuriininukleosideillä
CO4600681A1 (es) * 1996-02-24 1998-05-08 Boehringer Ingelheim Pharma Composicion farmaceutica para la modulacion inmunitaria
US6589940B1 (en) * 1997-06-06 2003-07-08 Dynavax Technologies Corporation Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
DE19803453A1 (de) * 1998-01-30 1999-08-12 Boehringer Ingelheim Int Vakzine
EP1272215B1 (en) * 2000-04-14 2007-10-10 Intercell AG Pharmaceutical preparations comprising modified peptides
HU228264B1 (en) * 2000-06-08 2013-02-28 Intercell Ag Immunostimulatory oligodeoxynucleotides
AT410173B (de) * 2000-06-08 2003-02-25 Cistem Biotechnologies Gmbh Antigene zusammensetzung
EP1347775B1 (en) * 2001-01-05 2016-11-30 Valneva Austria GmbH Uses for polycationic compounds as vaccine adjuvants
EP1390494A2 (en) * 2001-05-21 2004-02-25 Intercell AG Method for stabilising of nucleic acids
US7276489B2 (en) * 2002-10-24 2007-10-02 Idera Pharmaceuticals, Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends
CA2388049A1 (en) * 2002-05-30 2003-11-30 Immunotech S.A. Immunostimulatory oligonucleotides and uses thereof
AU2004224746B2 (en) * 2003-03-24 2009-04-23 Valneva Austria Gmbh Improved vaccines
ES2351489T3 (es) * 2003-03-24 2011-02-07 Intercell Ag Vacunas mejoradas.

Similar Documents

Publication Publication Date Title
JP2003535146A5 (cg-RX-API-DMAC10.html)
US6140482A (en) Primary phosphoramidate internucleoside linkages and oligonucleotides containing the same
US7115579B2 (en) Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides
EP1390495B1 (en) Immunostimulatory oligodeoxynucleic molecules
DE60100814T2 (de) Immunstimulierende oligodeoxynukleotide
ES2543207T3 (es) Métodos y composiciones para la inhibición de respuestas inmunes innatas y autoinmunidad
US5672697A (en) Nucleoside 5'-methylene phosphonates
US7709449B2 (en) Nucleic acid-based compounds and methods of use thereof
EP1286695B1 (en) Antigenic composition comprising a polycationic peptide and inosine and cytosine
EP2361980B1 (en) Methods and compositions for inhibition of immune responses and autoimmunity
US7105495B2 (en) Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides
US20110040082A1 (en) Modifications of antimetabolite gemcitabine for incorporation in CpG oligonucleotides
US20030212029A1 (en) Modulation of oligonucleotides CpG-mediated immune stimulation by positional modification of nucleosides
JP2010148524A (ja) 5’cpg核酸およびその使用方法
JP2002531053A5 (cg-RX-API-DMAC10.html)
JP6106280B2 (ja) 阻害性オリゴヌクレオチド及びその使用
Kozlov et al. Nonenzymatic oligomerization reactions on templates containing inosinic acid or diaminopurine nucleotide residues
US6531589B1 (en) Base protecting groups and synthons for oligonucleotide synthesis
An et al. Synthesis of novel 3′-methylene H-phosphonate thymidines
Zatsepin et al. Synthesis of (2′ S)‐and (2′ R)‐2′‐Deoxy‐2′‐[(2‐methoxyethoxy) amino] Pyrimidine Nucleosides and Oligonucleotides
WO2004060323A2 (en) Novel inhibitors of poxvirus replication